

**We claim:**

**1. A peptide or its derivative of the structure:**

Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp (hereinafter referred as {4}),

or

5 Trp-Pro-Gly-Asn-Ile-Asp-Gly-Asp-Pro-Asn-Arg (hereinafter referred as {4'}),

or

Tyr-Thr-Met-Asn-Pro-Arg-Lys-Leu-Phe-Asp-Tyr (hereinafter referred as {5}),

or

Tyr-Asp-Phe-Leu-Lys-Arg-Pro-Asn-Met-Thr-Tyr (hereinafter referred as {5'}),

10 or

X-{4}-Y

or

X-{4'}-Y

or

15 X-{5}-Y

or

X-{5'}-Y

or

X-{4}-Ala-{5}-Y

20 or

X-{4'}-Ala-{5'}-Y

or

X-{5}-Ala-{4}-Y

or

25 X-{5'}-Ala-{4'}-Y

or

X-{4}-Cys-{5}-Y

or

X-{4'}-Cys-{5'}-Y

30 or

X-{5}-Cys-{4}-Y

or

X-{5'}-Cys-{4'}-Y

or

X-{4'}-(Gly-Gly-Gly-Ser)<sub>n</sub>-{5'}-Y

5 or

X-{4'}-(Gly-Gly-Gly-Ser)<sub>n</sub>-{5'}-Y

or

X-{5'}-(Gly-Gly-Gly-Ser)<sub>n</sub>-{4'}-Y

or

10 X-{5'}-(Gly-Gly-Gly-Ser)<sub>n</sub>-{4'}-Y

or

Cys-{4'}-Ala-{5'}-Cys

or

15 Cys-{4'}-Ala-{5'}-Cys

or

Cys-{5'}-Ala-{4'}-Cys

20 or

Cys-{5'}-Ala-{4'}-Cys

or

Ala-{4'}-Ala-{5'}-Ala

25

or

Ala-{4'}-Ala-{5'}-Ala

or

30 Ala-{5'}-Ala-{4'}-Ala

or

Ala-{5'}-Ala-{4'}-Ala



wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein X is Acetyl group or other customary N-terminal protecting groups;

wherein Y is amine, ethylamine, or other customary C terminal protecting groups;

wherein n = 1 to 3..

10 2. A pharmaceutical composition comprising one or a plurality of said peptide or its derivatives in claim 1.

3. Said peptide or its derivatives in claim 1 wherein one or a plurality of amino acids are in D-form.

15 4. A pharmaceutical composition comprising one or a plurality of said peptide or its derivatives in claim 3.

20 5. Said peptide or its derivatives in claim 1 wherein one amino acid is removed, replaced, or added to from a new molecule.

6. A pharmaceutical products comprising one or a plurality of said peptide or its derivatives in claim 5.

25 7. Said peptide or its derivatives in claim 1 wherein either the C-terminal protecting group or the N-terminal protecting group is removed if there is any.

8. A pharmaceutical product comprising one or a plurality of said peptide or its derivatives in claim 7.

30 9. A method for the treatment of diseases related to angiogenesis by administering to a patient a

therapeutic amount of said peptides or its derivatives in claim 1.

10. The method in claim 9 wherein said diseases comprises lung cancer, liver cancer, brain cancer, colon cancer, impairment of vision induced by late-staged diabetes, and other diseases related to angiogenesis.

11. A method for the treatment of diseases related to angiogenesis by administering to a patient a pharmaceutical composition comprising of said peptides or its derivatives in claim 1

12. The method in claim 11 wherein said diseases comprises lung cancer, liver cancer, brain cancer, colon cancer, impairment of vision induced by late-staged diabetes, and other diseases related to angiogenesis.

TO6050" 90027660